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Background: Using abdominal aortic aneurysm (AAA) as a model, this case–control study used electronic medical
record (EMR) data to assess known risk factors and identify new associations.
Methods: The study population consisted of cases with AAA (n =888) and controls (n =10,523) from the Geisinger
Health System EMR in Central and Northeastern Pennsylvania. We extracted all clinical and diagnostic data for these
patients from January 2004 to December 2009 from the EMR. From this sample set, bootstrap replication
procedures were used to randomly generate 2,500 iterations of data sets, each with 500 cases and 2000 controls.
Estimates of risk factor effect sizes were obtained by stepwise logistic regression followed by bootstrap aggregation.
Variables were ranked using the number of inclusions in iterations and P values.
Results: The benign neoplasm diagnosis was negatively associated with AAA, a novel finding. Similarly, type 2
diabetes, diastolic blood pressure, weight and myelogenous neoplasms were negatively associated with AAA.
Peripheral artery disease, smoking, age, coronary stenosis, systolic blood pressure, age, height, male sex, pulmonary
disease and hypertension were associated with an increased risk for AAA.
Conclusions: This study utilized EMR data, retrospectively, for risk factor assessment of a complex disease. Known
risk factors for AAA were replicated in magnitude and direction. A novel negative association of benign neoplasms
was identified. EMRs allow researchers to rapidly and inexpensively use clinical data to expand cohort size and
derive better risk estimates for AAA as well as other complex diseases.
Keywords: Aortic Aneurysm, Abdominal, Electronic medical record, Neoplasms, Benign, Risk factors, Blood pressure,
Diabetes mellitus, Type 2, Case–control studiesBackground
Epidemiological research studies on risk factors are
traditionally performed with case–control or cohort
studies, requiring a considerable sample size, cost and
time investment. Electronic medical records (EMR)
contain a wealth of phenotypic information with high
potential to replace costly traditional epidemiological
methods for purposes such as determining disease risk
factors. In this study we utilized an extensive EMR to
determine risk factors associated with incident cases of* Correspondence: dtsmelser@geisinger.edu
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unless otherwise stated.abdominal aortic aneurysm (AAA) in a population-based
case–control study from the Geisinger Health System
(GHS) serving populations in Central and Northeastern
Pennsylvania [1,2]. Pennsylvania has one of the highest
rates of mortality from AAA in the USA [3].
AAA is defined as a dilatation of >3 cm in the infrarenal
aorta [4-7]. A leading cause of death in the United States,
AAAs often exist undetected until the aneurysm ruptures,
with a concomitant fatality rate of up to 90% [5,8-11].
Rupture can be prevented by endovascular repair or trad-
itional open aortic surgery, which is usually performed
after the aneurysm reaches a diameter of ≥5.5 cm. Since
AAAs can be detected non-invasively by ultrasonography
and can be surgically repaired, AAA is an ideal disease forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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invasive, relatively inexpensive and has a sensitivity and
specificity of ≥99% [9,12-14]. Currently, the United States
Preventative Services Task Force (USPSTF) recommends
one AAA ultrasound screening for males, 65 to 75 years
of age who smoked ≥100 cigarettes in their lifetime
[15,16]. The USPSTF does not recommend screening
for women, although females with AAA have a poorer
prognosis and higher mortality rate in the event of a
rupture [17-23]. Medicare began covering ultrasonog-
raphy screening in 2007 for the initial “Welcome to
Medicare” enrollment examination for men 65 to 75 years
of age who have ever smoked or those with a family his-
tory of AAA [24]. According to recent studies fewer than
30% of eligible patients are actually screened [16,25]. The
current guidelines are under-utilized and exclude many at
increased risk [26]. Additionally, a recent retrospective
analysis indicated that 77% of ruptured AAA patients were
unaware of their AAA prior to the rupture, despite a visit
to a clinician within the past 5 years [27].
Current risk prediction based only on sex, age and
smoking has low sensitivity and specificity, and therefore
is used relatively infrequently. Better risk estimates and
risk prediction models should improve utility and
utilization. Our study established the feasibility of utiliz-
ing an EMR to identify novel risk factors and replicate risk
factor associations with the incidence of AAA found in
the literature. It also demonstrated the utility of EMRs to
rapidly expand the available cohort size for identifying risk
factors and obtaining refined effect size estimates.
Methods
Study population
GHS provides primary and specialty care to a highly
stable population of 2.6 million residents in Central and
Northeastern Pennsylvania [2]. Geisinger serves a large
catchment area. We restricted the region to those re-
gional divisions (counties) where Geisinger serves
more than 10% of the county population. Among these
counties Geisinger serves about half of their two mil-
lion inhabitants. The cases and controls for this study
consisted of individuals with AAA and individuals
without diagnosed AAA from GHS with clinical records
in the EMR from January 2004 to December 2009. Cases
(n =888; 686 males and 202 females) were identified by
the following criteria: International Classification of
Diseases, 9th Revision (ICD-9) codes for AAA (441.3,
441.4), Current Procedural Terminology (CPT) codes
(34800, 34802, 34803, 34804, 34805, 34830, 34831,
34832, 35081, 35082, 35091, 35092, 35102, 35103,
35131, 35132), or referral to the GHS Department of
Vascular Surgery with an imaging study (such as ultra-
sound, computed tomography scan or MRI) to confirm
an infrarenal aortic diameter >3.0 cm. All AAA casesin GHS are referred to the Department of Vascular
Surgery, which diminishes possible ascertainment bias.
Statistical analyses were performed using bootstrap
aggregation (see Statistical Analyses section below for
details). A control sample was selected to reflect popu-
lation census demographics from all available patients
without known AAA at the start of the study (n =10,523;
4,132 males and 6,391 females) enrolled in the GHS
MyCode® biobanking repository [1]. All individuals in the
study were Caucasian, which reflects the homogeneous
ethnicity of the population in the GHS service area and
the demographics of the disease. The MyCode® repository
consists of individuals attending primary care sites in
the communities served by GHS. Inclusion criteria
were: adults >18 years of age, patient at a GHS primary
care clinic, and no diagnosis of dementia. The MyCode®
participants are representative of the demographic and
clinical characteristics of the GHS outpatient population.
Individuals gave written informed consent to allow their
EMR data to be used for research purposes and to have
biological specimens stored in the biobank.
GHS has utilized EMR since 1996, and implemented a
data warehouse system for research data mining and
analysis in 2008 [1]. This data warehouse includes the
outpatient records of the patients seen by primary care
and specialty providers. Analysts in the biostatistical
core extract and de-identify the data through a data
broker system before the investigators receive the dataset.
The study was approved by the Institutional Review Board
of GHS.
Data source
Demographic and clinical variables of interest were
extracted from the Geisinger EMR. Clinical risk fac-
tors were selected from the literature or were those
of biological interest based on AAA pathobiology
[7-9,11,28-42]. All diagnoses, laboratory measures and
clinical values from primary care and specialty clinic visits
(as of the date of the data extraction) were extracted.
Age was defined as the age at AAA diagnosis for
cases, and age at data extraction for the controls. In-
dividuals >89 years of age were removed to protect
potential identification of subjects. The ICD-9 codes
and diagnoses used to define these variables are listed
in Table 1. Since there were a number of infrequent
diagnoses among the 565 distinct ICD-9 codes used for
the data extraction, the codes were collapsed into 17 cat-
egories to reduce the number of variables for modeling.
All variables were examined for consistency and dis-
tribution. Extreme, clinically or biologically implaus-
ible values were attributed to data entry error and
excluded from the analysis. The median was used as a
measure of centrality for continuous variables of the
cleaned data set.
Table 1 ICD-9 diagnostic codes and assigned categories
used to identify comorbidities
Diagnostic category ICD-9 codes
Arterial dissection 443.21–443.29
Atherosclerosis 440
Benign neoplasm 210.00–229.9, 238.8, 238.9
Cerebral thrombosis 434, 434.01, 434.1, 437.1
Cerebrovascular disease 434.11, 434.91, 435.8, 435.9,
436, 437, 437.0A, 437.4,
437.6–437.9
Coronary stenosis 411.81, 414.00–414.9
Cranial artery stenosis 433–433.9, 434.9, 435–435.3
Hypertension 401.0–405.99
Intracranial aneurysm 430, 437.3
Intracranial hemorrhage 431, 432.1, 432.9
Kidney disease 585.3–585.9, 586
Malignant neoplasm 140.00–209.6, 230.00–234.9,
235.1–238.3
Myelogenous neoplasm 200–208.9, 238.4–238.7,
238.71–238.73, 238.75, 238.76,
238.79, 272.2
Peripheral artery disease 440.21, 440.22, 440.3, 440.31,
440.32, 443.9
Pulmonary disease 491.00–492.8, 493.2, 496, 518.1
Type 1 diabetes 250.01, 250.03, 250.11, 250.13,
250.2, 250.23, 250.41, 250.43,
250.51, 250.53, 250.61, 250.63,
250.71, 250.73, 250.81, 250.83,
250.93
Type 2 diabetes 250.00, 250.02, 250.1, 250.12,
250.22, 250.4, 250.42, 250.5,
250.52, 250.6, 250.62, 250.7,
250.72, 250.8, 250.82, 250.9,
250.92
ICD-9, International Classification of Diseases (9th Revision).
Figure 1 Study design. MyCode® is the biobank at GHS, Geisinger
Health System. AAA, abdominal aortic aneurysm; EMR, electronic
medical record.
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U.S. Census Bureau data for 2010 [43] for all counties
within the GHS service area were used to standardize
the control sample for population age and sex. Trad-
itional bootstrap methods [44,45], with replacement,
were used to randomly generate 2,500 iterations of data
sets of 2,000 controls and 500 AAA cases with complete
data (Figure 1). Each set of controls was selected to re-
flect the census age and sex demographic structure.
Younger individuals, especially males, are underrepre-
sented among patients in health care systems. To pre-
vent oversampling of individuals under 35 years of age,
census age classes (18,35] were collapsed into a single
class. The number of controls was limited to 2,000 to
ensure that the sampling of young males was not ex-
treme. Cases were selected at random from the 888
available cases. The 2,500 bootstrap data sets were ana-
lyzed using logistic regression with AAA as the outcomevariable and 26 explanatory variables. Variable selection
was achieved by bidirectional stepwise elimination using
Aikaike’s information criterion (AIC) [46] to evaluate model
fit. A final model was generated using variables that were
consistently retained in most bootstrap iterations. A second
set of 2,500 bootstrap data sets were generated and
analyzed using logistic regression with the final model
of a fixed number of variables (Table 2), i.e., each bootstrap
set was analyzed with the same model [47]. Regression esti-
mates were recorded for each iteration and the estimates
aggregated using meta-analytic techniques (using random-
effects weighting). Variables were ranked by how often they
were retained in the model, and by the P value, which was
based on the mean z score weighted by the number of
iterations the corresponding variable was included in
the model. The 14 highest ranked variables were then fixed
in a second bootstrap analysis (no stepwise elimination).
Table 2 Risk factor estimates for AAA
Variable Meta* estimate Meta* SE P† OR 95% CI
Peripheral artery disease 1.49 0.0040 3.71E-16 4.42 3.08–6.35
Smoking, ever/never 1.36 0.0036 3.92E-15 3.91 2.77–5.53
Coronary stenosis 1.07 0.0032 2.01E-12 2.91 2.15–3.93
Type 2 diabetes −0.84 0.0043 1.69E-05 0.43 0.29–0.64
Systolic blood pressure 0.03 0.0001 2.20E-07 1.03 1.02–1.05
Diastolic blood pressure −0.05 0.0003 1.84E-05 0.95 0.93–0.98
Age 0.05 0.0001 1.63E-15 1.05 1.04–1.06
Weight −0.01 3.94E-05 9.13E-07 0.99 0.98–0.99
Height 0.12 0.0001 2.78E-05 1.13 1.06–1.20
Sex 0.65 0.0044 0.00172 1.92 1.24–2.97
Benign neoplasm −0.39 0.0029 0.00263 0.67 0.51–0.89
Pulmonary disease 0.54 0.0035 0.00061 1.72 1.24–2.38
Hypertension 0.62 0.0038 0.00056 1.86 1.28–2.72
Myelogenous neoplasm −0.32 0.0032 0.02131 0.73 0.54–0.99
Controls chosen randomly from all non-AAA subjects (2,500 iterations, 500 cases, 2,000 controls), but weighted on sex and age (5 y classes) to match census
population structure for the GHS catchment area. For outline of the study design, see Figure 1.
Age classes below 35 were consolidated into a single age class to avoid oversampling the sparse classes of [18,20,25] and [25,30]. These classes are typically
underrepresented in physician visits.
*Meta.Est is the meta-analysis estimate (random effects, variance weighted, aggregate) of the betas from bootstrap iterations, Meta SE is the standard error of
this estimate.
†Two-sided P-value.
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two-sided. Analyses were performed in R v.2.16.2, 64-bit (R
Foundation for Statistical Computing; www.R-project.org,
Vienna, Austria) [48] using the glm and rmeta packages.
Results
We identified 888 AAA cases from the GHS Department
of Vascular Surgery. We also identified a pool of 10,523
patients without AAA from the Geisinger EMR who
were consented into the MyCode® biobanking project
with complete data for the variables of interest (Figure 1).
Using 2010 census demographics, we standardized the
control sample sets to match the demographics of the
population residing in the GHS catchment area. After
randomly generating 2,500 iterations of 500 cases and
2,000 controls each, we used meta-analysis and weighted
the variables by how often they appeared in the 2,500 it-
erations and their significance (P value). The highest
ranking variables were included in a second bootstrap
analysis to obtain unbiased estimates (Table 2). Periph-
eral artery disease (PAD), smoking, coronary stenosis,
systolic blood pressure, age, height (taller stature), male
sex, pulmonary disease and hypertension were signifi-
cantly associated with an increased risk for AAA. Type 2
diabetes mellitus (T2DM), diastolic blood pressure, weight,
benign neoplasms and myelogenous neoplasms had a sig-
nificantly negative association with AAA. Blood pressure
remained in the model as diastolic and systolic measure-
ments, as well as the diagnosis of hypertension.The significant association between AAA and be-
nign neoplasms was a novel finding. We compared all
AAA cases with at least one benign neoplasm diagnosis
(n = 365) to all controls with a benign neoplasm diagnosis
(n = 5,419) (Table 3). Some individuals had more than one
type of neoplasm. Benign neoplasm of the skin was the
most common subtype in controls (73%), significantly
more common than in cases (59%, P <0.001). Benign neo-
plasm of the digestive system was the most prevalent in
cases (61%) as compared to controls (43%) and this differ-
ence was also significant (P <0.001). Benign neoplasm of
the mouth/throat was only borderline significantly differ-
ent between cases and controls, the remaining subtypes
were not significantly different.
Discussion
This study demonstrated the feasibility of utilizing EMR
data in a retrospective study for risk factor assessment of
AAA, a complex disease. Previous studies have identified
a number of risk factors for AAA including age, male
sex, and smoking [28-38,49-52] which were confirmed
as important risk factors in the current study (Figure 2;
Table 2). Age of the patient has also been significantly
associated with survival based on repair type [53]. Strong
and consistent evidence of an association of smoking
with AAA warranted the inclusion of AAA in the Surgeon
General’s report on The Heath Consequences of Smoking
in 2004 [54]. Smoking also affects AAA expansion and rup-
ture [36,55,56]. In addition, PAD [33,34,36,56], coronary
Table 3 Comparison of subclasses of benign neoplasms between AAA cases and controls
Type of neoplasm Cases (n = 365) with neoplasm Controls (n = 5419) with neoplasm P†
n % n %
Skin 216 59.18 3962 73.11 <0.001
Digestive 226 61.92 2317 42.76 <0.001
Benign Neoplasm NOS* 61 16.71 764 14.1 0.164
Lipoma 31 8.49 632 11.66 0.074
Hemangioma 12 3.29 248 4.58 0.296
Endocrine gland 22 6.03 211 3.89 0.053
Eye 10 2.74 106 1.96 0.33
Brain/nervous 7 1.92 104 1.92 0.98
Soft tissue 2 0.55 88 1.62 0.126
Mouth/throat 11 3.01 82 1.51 0.048
Respiratory 6 1.64 37 0.68 0.051
Urinary 2 0.55 21 0.39 0.654
Bone 0 0 10 0.18 0.969
*NOS = Not otherwise specified.
Cases and controls used for this analysis include those with at least one diagnosis of benign neoplasm. Controls which were selected at least 100 times in the
bootstrap replication sets to provide a more closely matched comparison group.
†χ2or Fisher’s exact test where appropriate, P- values are 2-tailed.
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height [30,31,37,41], pulmonary disease [39,57], a diagno-
sis of hypertension [28,30,32,34,37,41,49,55] and malig-
nant neoplasms [58,59] were all significantly associated
with an increased AAA risk in this population. The
negative association with T2DM replicated published
AAA epidemiologic studies [23,30,34-36,38,55,60]. Dia-
betes has also been associated with a decrease in growth
of AAA [36]. A negative association was also found with
weight. Height was found to be significantly associated
with AAA, independent of body mass index (BMI), repli-
cating published findings for AAA [30,31,36,41]. We found
a negative, but not statistically significant, association of
BMI with AAA. In previous studies the association of BMI
with AAA has been inconsistent, many studies have found
a positive association with AAA [31,38,61], while othersFigure 2 Forest plot of risk factors for AAA identified using EMR data
variables; and B, continuous variables. Odds ratios and 95% confidence inte
artery disease; T2DM, type 2 diabetes mellitus; BP, blood pressure.have found a negative association [36] or no association
[32,37,41,62].
We found a negative association of myelogenous
(OR =0.73, P =0.021) neoplasms with AAA. An associ-
ation of AAA and cancer has been reported in two
studies when comparing AAA cases to patients with
atherosclerotic occlusive disease (AOD) [58,59]. The
sample size in the first study was small, 69 AAA and
61 AOD cases [59]. The second study with a larger
group, 298 AAA and 151 AOD patients also found an
association of AAA with cancer, but it was not statistically
significant when controlling for the confounders of age
and smoking [58].
The negative association of benign neoplasms with
AAA identified in the current study is intriguing. The most
common type of neoplasm was of the skin, significantly. For scaling purposes, the data are separated into. A, discrete
rvals for the variables associated with AAA are shown. PAD, peripheral
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digestive system were more common in cases. The identi-
fied association is biologically plausible since two genes
(CDKN2BAS and DABP2) with strong associations to
AAA have roles in cell growth [63,64]. Further research is
necessary and may provide a clue to the molecular biology
of AAA. Since the current study is cross-sectional, we
cannot determine causation, but rather the results reveal
correlations between incident AAA and various clinical
variables.
The major strength of this study lies in the demonstra-
tion that EMR data collected as part of standard clinical
care is suitable for retrospective epidemiologic analysis.
This has profound implications for future use of EMR
data for other risk analyses. The Medicare and Medicaid
EHR Incentive Program provides incentives to eligible
health care providers, and EMR data should become
more readily available to a majority of researchers [2]. A
limitation of EMRs, and this study, is that EMRs are de-
signed for clinical utility rather than research purposes.
Consequently, data entry errors such as missing observa-
tions, inconsistent entries, outliers or improbable values
must be resolved prior to analysis. Approaches to using
EMR data are being investigated by a number of groups
including the NIH-funded electronic Medical Record
and Genomics (eMERGE) Network [65,66] and the Health
Maintenance Organization Research Network (HMORN)
Virtual Data Warehouse (VDW) project [67]. Despite gaps
and inconsistencies in EMR data, the information avail-
able for our study was of sufficient quality to identify the
major known risk factors for AAA. We focused on identi-
fying risk factors for the incidence of AAA, not AAA pro-
gression, which likely has different risk factors.
As Geisinger is the primary health care provider for
the population residing in Northeastern Pennsylvania,
the EMR contains extensive medical history for all the
patients in our study. The EMR allows us to mitigate
several issues inherent in epidemiologic research, such
as selection bias and unknown confounders. A major
advantage of the EMR is that our study had much higher
participation rates than traditional epidemiological stud-
ies, since data could be extracted from the EMR post
facto. The proportion of elderly individuals in Central
and Northeastern Pennsylvania is higher than the national
average, increasing the number of AAA cases in the
current study. A bias inherent to EMRs includes over-
representation of sick participants and underrepresenta-
tion of the young, who tend to be healthy and less prone
to seeking medical care. In our case, MyCode® recruits pa-
tients from primary care in addition to tertiary care, and
the general health of the participants, therefore, is more
representative of the general population. Generalizability
of the results to other populations is unknown, although it
is encouraging that all the known major risk factors foundin previous studies in other populations were detected in
our study. Previous studies have indicated that family his-
tory is a significant risk factor [30,39,51,68,69] but family
history of AAA was not recorded in the Geisinger EMR.
Conclusions
One of the goals of the study was to identify risk factors
for AAA which could then be used to refine the eligibility
criteria for AAA ultrasonography screening programs.
The current screening guidelines have low sensitivity
and specificity, and an improved risk prediction model
would be of great public health benefit [38,70]. Future
work on AAA risk prediction models should include ge-
notypes of genetic variants [63,71-73] along with the
recognized demographic and clinical variables. We would
also like to study risk factors for progression and growth
rates of AAAs. EMRs allow researchers to rapidly and
inexpensively use clinical data to expand cohort size to
derive better estimates for AAA as well as other complex
diseases.
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